Immunocore Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Immunocore Holdings
IMCR Stock  USD 32.30  0.26  0.81%   
Immunocore Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immunocore Holdings' valuation are provided below:
Gross Profit
386.2 M
Profit Margin
(0.09)
Market Capitalization
1.6 B
Enterprise Value Revenue
3.7395
Revenue
400 M
There are over one hundred nineteen available fundamental trends for Immunocore Holdings, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm Immunocore Holdings' regular fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/28/2026, Market Cap is likely to drop to about 1.3 B. In addition to that, Enterprise Value is likely to drop to about 1.1 B

Immunocore Holdings Total Revenue

312.45 Million

Check Immunocore Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunocore Holdings' main balance sheet or income statement drivers, such as Interest Expense of 12.8 M, Other Operating Expenses of 189.4 M or Income Tax Expense of 12.8 M, as well as many indicators such as Price To Sales Ratio of 5.58, Dividend Yield of 0.0 or PTB Ratio of 4.36. Immunocore financial statements analysis is a perfect complement when working with Immunocore Holdings Valuation or Volatility modules.
  
Build AI portfolio with Immunocore Stock
Check out the analysis of Immunocore Holdings Correlation against competitors.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Immunocore Holdings Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities230.7 M219.7 M61.6 M
Slightly volatile
Total Current Liabilities259 M246.7 M84.7 M
Slightly volatile
Other Liabilities5.1 M5.3 M20.4 M
Slightly volatile
Net Tangible Assets336.1 M320.1 M185.1 M
Slightly volatile
Accounts Payable15.2 M24.4 M10.1 M
Slightly volatile
Net Receivables49.7 M74 M33.4 M
Slightly volatile
Other Stockholder Equity625.3 M1.2 B375.6 M
Slightly volatile
Total Current Assets1 B996.7 M370.6 M
Slightly volatile
Property Plant Equipment33.1 M36.4 M24.1 M
Slightly volatile
Total Assets583.9 M1.1 B376.3 M
Slightly volatile
Short and Long Term Debt Total41.4 M43.6 M64.3 M
Slightly volatile
Total Stockholder Equity249.2 M381 M147.9 M
Slightly volatile
Property Plant And Equipment Net48.5 M50.2 M33.4 M
Slightly volatile
Cash342.2 M467.7 M225.1 M
Slightly volatile
Non Current Assets Total65.2 M70.5 M43.3 M
Slightly volatile
Non Currrent Assets Other11.1 M20.3 M6.6 M
Slightly volatile
Long Term Debt412.8 M393.1 M92.1 M
Slightly volatile
Cash And Short Term Investments446.9 M864.2 M276 M
Slightly volatile
Common Stock Shares Outstanding44.7 M50.3 M34.6 M
Slightly volatile
Liabilities And Stockholders Equity583.9 M1.1 B376.3 M
Slightly volatile
Non Current Liabilities Total461.5 M439.5 M153.8 M
Slightly volatile
Total Liabilities720.5 M686.2 M251.1 M
Slightly volatile
Net Invested Capital812.9 M774.2 M240.5 M
Slightly volatile
Property Plant And Equipment Gross66.7 M111 M42.3 M
Slightly volatile
Net Working Capital787.5 M750 M258.1 M
Slightly volatile
Intangible Assets3513694.6 M
Pretty Stable
Current Deferred Revenue553.9 K583 K26.9 M
Slightly volatile
Short and Long Term Debt15.3 M17.2 M18.8 M
Slightly volatile
Short Term Debt1.9 M2 M17.8 M
Slightly volatile
Common Stock Total Equity800900982
Slightly volatile
Common Stock131.6 K136 K87.6 K
Slightly volatile
Good Will327.7 K368.6 K402.4 K
Slightly volatile

Immunocore Holdings Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses189.4 M331.3 M112.7 M
Slightly volatile
Interest Income8.3 M16.5 M4.4 M
Slightly volatile
Depreciation And Amortization4.2 M2.4 M5.9 M
Slightly volatile
Selling General Administrative111.8 M165.4 M70.5 M
Slightly volatile
Selling And Marketing Expenses7.3 M7.6 M53.5 M
Slightly volatile
Total Revenue312.4 M297.6 M91.6 M
Slightly volatile
Research Development135.9 M204.5 M105.5 M
Slightly volatile
Total Operating Expenses209.7 M325.1 M157.4 M
Slightly volatile
Reconciled Depreciation5.1 M3.3 M6.4 M
Slightly volatile
Cost Of Revenue5.9 M6.2 M69.2 M
Slightly volatile

Immunocore Holdings Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation4.7 M3.3 M5 M
Pretty Stable
Total Cash From Financing Activities8.7 M9.2 M67.9 M
Slightly volatile
End Period Cash Flow305.6 M467.7 M199.2 M
Slightly volatile
Stock Based Compensation27.2 M37.7 M13.6 M
Slightly volatile
Begin Period Cash Flow286 M455.7 M178.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.585.872629.122
Slightly volatile
PTB Ratio4.364.586214.3411
Slightly volatile
Days Sales Outstanding86.290.7405484
Slightly volatile
Book Value Per Share3.987.56833.5457
Slightly volatile
Average Payables8.5 M11.1 M9.7 M
Slightly volatile
Stock Based Compensation To Revenue0.120.12670.1604
Slightly volatile
Capex To Depreciation1.41.32880.6726
Slightly volatile
PB Ratio4.364.586214.3411
Slightly volatile
EV To Sales4.224.447225.753
Slightly volatile
Payables Turnover0.240.2553.4764
Slightly volatile
Sales General And Administrative To Revenue1.592.941.991
Slightly volatile
Research And Ddevelopement To Revenue0.650.68712.6012
Slightly volatile
Capex To Revenue0.01390.01460.1023
Slightly volatile
Cash Per Share18.0217.16447.4797
Slightly volatile
Days Payables Outstanding1.3 K1.4 K759
Slightly volatile
Intangibles To Total Assets0.00.09.0E-4
Slightly volatile
Current Ratio2.94.04033.4958
Pretty Stable
Tangible Book Value Per Share3.977.56833.539
Slightly volatile
Receivables Turnover3.024.02252.1994
Slightly volatile
Shareholders Equity Per Share3.987.56833.5457
Slightly volatile
Debt To Equity0.110.11430.6255
Very volatile
Capex Per Share0.110.08620.1124
Slightly volatile
Average Receivables25.2 M40.8 M24.4 M
Slightly volatile
Revenue Per Share6.215.91052.1104
Slightly volatile
Interest Debt Per Share1.051.10691.7079
Slightly volatile
Debt To Assets0.03880.04080.1518
Slightly volatile
Price Book Value Ratio4.364.586214.3411
Slightly volatile
Days Of Payables Outstanding1.3 K1.4 K759
Slightly volatile
Ebt Per Ebit0.40.42110.8594
Slightly volatile
Company Equity Multiplier4.152.8013.6443
Very volatile
Long Term Debt To Capitalization0.09340.09830.2457
Pretty Stable
Total Debt To Capitalization0.09750.10260.2954
Very volatile
Debt Equity Ratio0.110.11430.6255
Very volatile
Quick Ratio2.914.0133.5787
Very volatile
Net Income Per E B T1.951.85941.0235
Slightly volatile
Cash Ratio2.171.89592.5843
Very volatile
Days Of Sales Outstanding86.290.7405484
Slightly volatile
Price To Book Ratio4.364.586214.3411
Slightly volatile
Fixed Asset Turnover6.225.92242.3009
Slightly volatile
Debt Ratio0.03880.04080.1518
Slightly volatile
Price Sales Ratio5.585.872629.122
Slightly volatile
Asset Turnover0.170.27880.1659
Slightly volatile
Price Fair Value4.364.586214.3411
Slightly volatile

Immunocore Holdings Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B1.6 B1.3 B
Slightly volatile
Enterprise Value1.1 B1.2 B1.1 B
Slightly volatile

Immunocore Fundamental Market Drivers

Immunocore Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immunocore Holdings Financial Statements

Immunocore Holdings shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunocore Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in Immunocore Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunocore Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue583 K553.9 K
Total Revenue297.6 M312.4 M
Cost Of Revenue6.2 M5.9 M
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 2.94  1.59 
Research And Ddevelopement To Revenue 0.69  0.65 
Capex To Revenue 0.01  0.01 
Revenue Per Share 5.91  6.21 
Ebit Per Revenue(0.11)(0.12)

Pair Trading with Immunocore Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving together with Immunocore Stock

  0.69OSE OSE Pharma SAPairCorr

Moving against Immunocore Stock

  0.75GXEA Galapagos NVPairCorr
  0.69EQ EquilliumPairCorr
  0.618VP1 AVRICORE HEALTH INCPairCorr
  0.57VALN Valneva SE ADRPairCorr
  0.37DNTH Dianthus TherapeuticsPairCorr
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY